Evidence mapPaperPMID 42141301Full record

ArticleClinical and experimental medicine2026

Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies.

Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang and 3 more

Abstract readValidation Study
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jialin Wu *Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Wenting Wei *Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Terry Cheuk-Fung YipMedical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Xinyi DengZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Bonan ChenDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Yang LyuDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Peiyao YuDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Tiejun FengDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Fuda XieDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China.
Ge ZhangLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Kangmin ZhuangGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Aimin LiGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wei KangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sir Y.K. Pao Cancer Center, Hong Kong, China. weikang@cuhk.edu.hk.

Funding

National Natural Science Foundation of China No. 82403017RGC General Research Fund CUHK14122725RGC Postdoctoral Fellowship Scheme No. UGC/GEN/562/3
6 · The paper itself

Abstract

Although many predictive models for metabolic dysfunction-associated steatotic liver disease (MASLD) have been developed, their performance remains suboptimal. We aimed to develop an interpretable machine learning (ML)-based plasma biomarker model for identifying prevalent MASLD. Data from the National Health and Nutrition Examination Survey (NHANES 2017-2020) were randomly divided into a training cohort (N = 2760) and an internal cohort (N = 1184). Eleven ML algorithms were employed to construct classification models. Model interpretability was visualized via the SHapley Additive exPlanations (SHAP) method. External validation of these models was further conducted using data from the Korea NHANES (KNHANES) 2019-2021. The association between the selected features and prevalent MASLD was evaluated using restricted cubic spline regression analysis. Feature selection was performed using LASSO regression and the Boruta algorithm. Key predictors included diabetes mellitus (DM), waist circumference (WC), age, hypertension, and atherogenic index of plasma (AIP). All evaluated ML algorithms demonstrated robust predictive capabilities, with areas under the curve (AUC) exceeding 0.70. Among these, the Extra Trees (ET) performed the best, achieving an AUC of 0.879 (95% CI 0.856-0.897) in the internal testing group and maintaining good performance in the external KNHANES cohort with an AUC of 0.822 (95% CI 0.815-0.829). The DeLong test revealed significant differences in AUC between ET and other algorithms. These findings suggest that age, WC, DM, hypertension, and AIP are informative features associated with prevalent MASLD. The ET model showed strong discriminative performance and may serve as a practical tool for MASLD screening.

Indexed as

BiomarkersFatty LiverMachine LearningAdultAlgorithmsClassification AlgorithmsFemaleHumansMaleNutrition SurveysObservational Studies as TopicPredictive Learning ModelsPrevalenceRepublic of KoreaBiomarkersMachine learningMetabolic dysfunction-associated steatotic liver diseasePlasma biomarkerScreening model

Identifiers

PMID42141301
PMCPMC13346284

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.